Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paperTong‐Yuan Yang, Vibha Jawa, Manuela Braun et al.|Molecular Therapy — Methods & Clinical Development|2022Cited by 113
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)Bart Corsaro, Meina Liang, Ivo Sonderegger et al.|Bioanalysis|2021Cited by 60
2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness ( <u>Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization)LiNa Loo, Robert Kubiak, Shannon Harris et al.|Bioanalysis|2022Cited by 35
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry PerspectiveHardik Mody, Vijay Upreti, K. OGASAWARA et al.|Clinical Pharmacology & Therapeutics|2023Cited by 26
Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug DevelopmentJochem Gokemeijer, Sofie Pattijn, Yi Wen et al.|The AAPS Journal|2023Cited by 22